ScionxBio announces collaboration to develop long-acting xRNA therapeutics

The Medical News ·
Health & Medicine United Kingdom

ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and…

Read original article on The Medical News →

Related news